Overview
Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study
Status:
Unknown status
Unknown status
Trial end date:
2015-12-01
2015-12-01
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
The primary aim of this study is to determine the effect of dopamine agonist therapy on insulin resistance in lean vs. obese women with polycystic ovary syndrome. Polycystic ovary syndrome (PCOS) is a common metabolic abnormality in women. The diagnosis of PCOS relies on a constellation of symptoms and signs (problems with ovulation, clinical and/or biochemical signs of hyperandrogenism and cystic ovaries). Though not a diagnostic feature, insulin resistance (IR) is a hallmark of PCOS and up to 80% women with PCOS have IR. Although IR is more significant in obese women with PCOS, even lean women can be insulin resistant. No current therapy addresses the problem of insulin resistance in PCOS. Studies have suggested a dopamine deficiency in patients with PCOS, which may underlie the insulin resistance and may have a pathogenetic role in the development of PCOS. No study to date has assessed the impact of dopamine agonist therapy on IR in patients with PCOS.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
IWK Health CentreTreatments:
BromocriptineCriteria
Inclusion Criteria:- women age 18 to 45 years with PCOS willing to maintain consistent weight for 3 month
study period
Exclusion Criteria:
- diabetes other conditions associated with insulin resistance previous intolerance to
dopamine agonist therapy concomitant medication that would interfere with dopamine
agonist therapy insulin resistance syndrome type A or Type B